Central Nervous System Partnering Terms and Agreements

Introduction

The Central Nervous System Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the central nervous system partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter central nervous system partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors central nervous system technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not.

This report contains over 1,500 links to online copies of actual central nervous system deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

The initial chapters of this report provide an orientation of central nervous system dealmaking and business activities. Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in central nervous system dealmaking since 2007 covering trends by year, deal type, stage of development, technology type and therapeutic indication. In addition the chapter includes an analysis of financial deal terms by stage at signing covering headline value, upfront payment, milestone payments and royalty rates. Analysis includes median values and distribution of values for each stage of development.

Chapter 3 provides a review of the leading central nervous system deals since 2007. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of central nervous system deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides comprehensive access to all central nervous system deals since 2007 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all central nervous system partnering deals signed and announced since 2007. The chapter is organized by specific central nervous system therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all central nervous system partnering deals signed and announced since 2007. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in central nervous system partnering and dealmaking since 2007.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of central nervous system technologies and products.

Central Nervous System Partnering Terms and Agreements provides the reader with the following key benefits:

• In-depth understanding of central nervous system deal trends since 2007
• Access central nervous system deal headline, upfront, milestone and royalty data
• Research hundreds of actual contracts between central nervous system partner companies
• Comprehensive access to over 1,500 links to actual central nervous system deals entered into by the world's biopharma companies
• Indepth review of central nervous system deals entered into by the leading fifty bigpharma companies
• Benchmark the key deal terms companies have agreed in previous deals
• Identify key terms under which companies partner central nervous system opportunities
• Uncover companies actively partnering central nervous system opportunities

Central Nervous System Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to central nervous system trends and structure of deals entered into by leading companies worldwide.

Central Nervous System Partnering Terms and Agreements includes:

• Trends in central nervous system dealmaking in the biopharma industry since 2007
• Analysis of central nervous system deal structure
• Access to headline, upfront, milestone and royalty data
• Access to hundreds of central nervous system deal contract documents
• Comprehensive access to over 1,500 central nervous system deal records
• The leading central nervous system deals by value since 2007
• Most active central nervous system dealmakers since 2007

In Central Nervous System Partnering Terms and Agreements, available deals and contracts are listed by:

• Headline value
• Upfront payment value
• Royalty rate value
• Stage of development at signing
• Deal component type
• Technology type
• Specific therapy indication

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Central Nervous System Partnering Terms and Agreements report provides comprehensive access to available deals and contract documents for over 1,500 central nervous system deals. Analyzing actual contract agreements allows assessment of the following:

• What are the precise central nervous system rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Current Partnering was established in 2007 and has become the leading publisher of deal term reports within the life sciences. Designed to translate research into commercial success, Current Partnering provides an opportunity for the dissemination of the latest trends in partnering activity across the life sciences.

Current Partnering report titles cover all aspects of partnering best practice and deal terms, providing users with the information and insight required to optimise their partnering activities.

Current Partnering is a trademark of Wildwood Ventures Ltd..

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in central nervous system dealmaking

• 2.1. Introduction
• 2.2. Central nervous system partnering over the years
• 2.3. Bigpharma central nervous system dealmaking activity
• 2.4. Bigpharma not active in Central nervous system
• 2.5. Central nervous system partnering by deal type
• 2.6. Central nervous system partnering by industry sector
• 2.7. Central nervous system partnering by stage of development
• 2.8. Central nervous system partnering by technology type
• 2.9. Central nervous system partnering by CNS indication

• 2.10. Average deal terms for central nervous system
  • 2.10.1. Central nervous system headline values
  • 2.10.2. Central nervous system upfront payments
  • 2.10.3. Central nervous system milestone payments
  • 2.10.4. Central nervous system royalty rates

Chapter 3 - Leading central nervous system deals

• 3.1. Introduction
• 3.2. Top central nervous system deals by value
• 3.3. Top central nervous system deals involving bigpharma

Chapter 4 - Bigpharma central nervous system deals

• 4.1. Introduction
• 4.2. How to use bigpharma partnering deals

• 4.3. Bigpharma central nervous system partnering company profiles
  • Abbott
  • Actavis
  • Allergan
  • Amgen
  • Aspen Pharmacare
  • Astellas
  • AstraZeneca
  • Baxter International
  • Bayer
  • Bayer Healthcare
  • Bayer Schering Pharma
  • Biogen Idec
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • CSL
  • Daiichi Sankyo
  • Dainippon Sumitomo
  • Dainippon Pharmaceutical
  • Eisai
  • Eli Lilly
  • Endo Pharmaceuticals
  • Forest Laboratories
  • Forest Laboratories Ireland
  • GlaxoSmithKline
  • Hospira
  • Johnson & Johnson
  • Kyowa Hakko Kirin
  • Lundbeck
  • Merck & Co
  • Merck KGaA
  • Mylan
  • Novartis
  • Otsuka
  • Pfizer
  • Purdue
  • Roche
  • Genentech
  • Sanofi
  • Servier
  • Shionogi
  • Shire
  • Takeda
  • Teva
  • UCB
  • Valeant
  • Watson

Chapter 5 - Central nervous system partnering contracts directory

• 5.1. Introduction

• 5.2. By deal type
  • Asset purchase
  • Assignment
  • Bigpharma outlicensing
  • Co-development
  • Collaborative R&D
  • Co-market
  • Contract service
  • Co-promotion
  • Development
  • Distribution
  • Equity purchase
  • Grant
  • Interests
  • Joint venture
  • Licensing
  • Litigation
  • Loan
  • Manufacturing
  • Marketing
  • Option
  • Promotion
  • Research
  • Royalty financing
  • Settlement
  • Spin out
  • Sub-license
  • Supply
  • Termination
  • Warranty

• 5.3. By stage of development
  • Discovery
  • Formulation
  • Marketed
  • Phase I
  • Phase II
  • Phase III
  • Preclinical
  • Regulatory

• 5.4. By technology type
  • Analysis
  • Assays
  • Biodefense
  • Biological compounds
  • Biomarkers
  • Biomaterials
  • Blood products
  • Clinical testing
  • Devices
  • Diagnostics
  • Discovery tools
  • DNA probes
  • Drug delivery
  • Enabling technology
  • Equipment
  • Facilities
  • Genomics
  • Implant
  • In vitro models
  • Natural product
  • Oligonucleotide
  • Orphan drug
  • Peptides
  • Processes
  • Proteomics
  • Radio/Chemo-therapy
  • Recombinant DNA
  • Research services
  • Research supplies
  • RNA therapeutics
  • Screening
  • Small molecules
  • Vaccines

Chapter 6 - Central nervous system dealmaking by indication

• 6.1. Introduction

• 6.2. Deals by therapeutic indication
  • Central Nervous System
  • Cerebral palsy
  • Creutzfeldt Jakob disease
  • Dizziness
  • Epilepsy
  • Guillain Barre syndrome
  • Headache
  • Meningitis
  • Bacterial
  • Haemophilus influenzae Type B
  • Meningococcal
  • Mycobacterium tuberculosis
  • Pneumococcal
  • Fungal
  • Viral
  • Migraine
  • Motor Neurone Disease (Amyotrophic Lateral Sclerosis/Lou Gehrig's Disease)
  • Multiple sclerosis
  • Nausea
  • Neuropathy
  • Pain
  • Neuralgia
  • Paralysis
  • Parkinson's disease
  • Restless leg syndrome
  • Spinal cord
  • Stroke
  • Traumatic Brain Injury
  • Vertigo
  • Weakness

Chapter 7 - Partnering resource center

• 7.1. Online partnering
• 7.2. Partnering events
• 7.3. Further reading on dealmaking

• About Wildwood Ventures
• Current Partnering
• Current Agreements
• Recent titles from CurrentPartnering
• Order Form - Reports
• Order Form - Therapy Reports

Appendices

• Appendix 1 - Directory of central nervous system deals by company A-Z 2007-2012
• Appendix 2 - Directory of central nervous deals by deal type 2007-2012
• Appendix 3 - Directory of central nervous system deals by stage of development 2007-2012
• Appendix 4 - Directory of central nervous system deals by technology type 2007-2012
• Appendix 5 - Deal type definitions

• Figure 1: Central nervous system partnering since 2007
• Figure 2: Bigpharma - top 50 - Central nervous system deals 2007 to 2012
• Figure 3: Bigpharma Central nervous system deal frequency - 2007 to 2012
• Figure 4: Inactive bigpharma in CNS 2007-2012
• Figure 5: Central nervous system partnering by deal type since 2007
• Figure 6: Central nervous system partnering by industry sector since 2007
• Figure 7: Central nervous system partnering by stage of development since 2007
• Figure 8: Central nervous system partnering by technology type since 2007
• Figure 9: Central nervous system partnering by CNS target since 2007
• Figure 10: Central nervous system deals with a headline value
• Figure 11: Central nervous system deal headline value distribution, US$million - discovery stage
• Figure 12: Central nervous system deal headline value distribution, US$million - preclinical stage
• Figure 13: Central nervous system deal headline value distribution, US$million - phase I stage
• Figure 14: Central nervous system deal headline value distribution, US$million - phase II stage
• Figure 15: Central nervous system deal headline value distribution, US$million - phase III stage
• Figure 16: Central nervous system deal headline value distribution, US$million - regulatory stage
• Figure 17: Central nervous system deal headline value distribution, US$million - marketed stage
• Figure 18: Summary median headline value by stage of development, 2007-2012
• Figure 19 Central nervous system deals with upfront payment values
• Figure 20: Central nervous system deal upfront payment distribution, US$million - discovery stage
• Figure 21: Central nervous system deal upfront payment distribution, US$million - preclinical stage
• Figure 22: Central nervous system deal upfront payment distribution, US$million - phase I stage
• Figure 23: Central nervous system deal upfront payment distribution, US$million - phase II stage
• Figure 24: Central nervous system deal upfront payment distribution, US$million - phase III stage
• Figure 25: Central nervous system deal upfront payment distribution, US$million - regulatory stage
• Figure 26: Central nervous system deal upfront payment distribution, US$million - marketed stage
• Figure 27: Summary median upfront payments by stage of development, 2007-2012
• Figure 28: Central nervous system deals with milestone payments
• Figure 29: Central nervous system deal milestone distribution, US$million - discovery stage
• Figure 30: Central nervous system deal milestone distribution, US$million - preclinical stage
• Figure 31: Central nervous system deal milestone distribution, US$million - phase I stage
• Figure 32: Central nervous system deal milestone distribution, US$million - phase II stage
• Figure 33: Central nervous system deal milestone distribution, US$million - phase III stage
• Figure 34: Central nervous system deal milestone distribution, US$million - regulatory stage
• Figure 35: Central nervous system deal milestone distribution, US$million - marketed stage
• Figure 36: Central nervous system deals with royalty rates, %
• Figure 37: Central nervous system deal royalty rate distribution, US$million - discovery stage
• Figure 38: Central nervous system deal royalty rate distribution, US$million - preclinical stage
• Figure 39: Central nervous system deal royalty rate distribution, US$million - phase I stage
• Figure 40: Central nervous system deal royalty rate distribution, US$million - phase II stage
• Figure 41: Central nervous system deal royalty rate distribution, US$million - phase III stage
• Figure 42: Central nervous system deal royalty rate distribution, US$million - regulatory stage
• Figure 44: Summary median royalty rate by stage of development, 2007-2012
• Figure 45: Top central nervous system deals by value since 2007
• Figure 46: Top central nervous system deals signed by bigpharma value since 2007
• Figure 47: Online partnering resources
• Figure 48: Forthcoming partnering events

Central Nervous System Partnering Terms and Agreements published by Current Partnering, a division of Wildwood Ventures Limited. This report consists of 595 Pages and the price starts from US $ 2695.

The contents of this page may be different from the latest version. Please contact us for details.